Int J Angiol
DOI: 10.1055/s-0041-1722875
Invited Paper

Effect of PCSK9 E670G and R46L Polymorphisms on Major Adverse Cardio-Cerebrovascular Events in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

1  Department of Cardiology, Vascular Medicine, Harapan Kita Hospital, National Cardiovascular Centre, Universitas Indonesia, Jakarta, Indonesia
,
Yulianto Yulianto
1  Department of Cardiology, Vascular Medicine, Harapan Kita Hospital, National Cardiovascular Centre, Universitas Indonesia, Jakarta, Indonesia
,
Hendra Simarmata
1  Department of Cardiology, Vascular Medicine, Harapan Kita Hospital, National Cardiovascular Centre, Universitas Indonesia, Jakarta, Indonesia
,
Abhirama Nofandra Putra
2  Department of Cardiology, Vascular Medicine, Gunung Jati Government Hospital, Kesambi - Cirebon, West Java, Indonesia
,
Erlin Listiyaningsih
3  Faculty of Medicine, University of Hamka, Ciledug, Banten, Indonesia
› Author Affiliations
Funding This study was funded by the National Cardiovascular Centre—Harapan Kita Hospital, Jakarta—Indonesia, with the grant number: LB. 02.02/XX.8/0224/2019

Abstract

Major adverse cardio-cerebrovascular events (MACCE) in ST-segment elevation myocardial infarction (STEMI) are still high, although there have been advances in pharmacology and interventional procedures. Proprotein convertase subtilisin/Kexin type 9 (PCSK9) is a serine protease regulating lipid metabolism associated with inflammation in acute coronary syndrome. The MACCE is possibly related to polymorphisms in PCSK9. A prospective cohort observational study was designed to confirm the association between polymorphism of E670G and R46L in the PCSK9 gene with MACCE in STEMI. The Cox proportional hazards model and Spearman correlation were utilized in the study. The Genotyping of PCSK9 and ELISA was assayed.

Sixty-five of 423 STEMI patients experienced MACCE in 6 months. The E670G polymorphism in PCSK9 was associated with MACCE (hazard ratio = 45.40; 95% confidence interval: 5.30–390.30; p = 0.00). There was a significant difference of PCSK9 plasma levels in patients with previous statin consumption (310 [220–1,220] pg/mL) versus those free of any statins (280 [190–1,520] pg/mL) (p = 0.001).

E670G polymorphism of PCSK9 was associated with MACCE in STEMI within a 6-month follow-up. The plasma PCSK9 level was higher in statin users.

Ethical Approval

All procedures performed in the study involving human participants were following the ethical standards and had been reviewed by the Institutional Review Board and Local Ethics Committee of National Cardiovascular Centre—Harapan Kita Hospital in Jakarta, Indonesia (No: LB.02.01/VII/307/KEP.078/2–18) and conforms to the ethical guidelines of the 1964 Helsinki declaration and its amendments, and the 2016 International Ethical Guidelines for Health-related Research Involving Humans (CIOMS and WHO).


Note

Informed consent was obtained from all individuals included in the study.




Publication History

Publication Date:
18 February 2021 (online)

© 2021. International College of Angiology. This article is published by Thieme.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA